ROCHE DRUG CUTS LUNG CANCER DEATH RISK 44%

Roche's divarasib extended median overall survival to 17.7 months versus 12.0 months for the approved rivals sotorasib and adagrasib, in a head-to-head Phase III trial enrolling 338 patients with KRAS G12C-mutated non-small cell lung cancer. The drug also cut the risk of death by 44% and progression-free survival rose to 9.8 months against 5.7 months for the comparator arm. Roche ($RHHBY) presented the Krascendo 1 data at ESMO's Presidential Symposium and published it simultaneously in the New England Journal of Medicine.